SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001714899-22-000109
Filing Date
2022-07-27
Accepted
2022-07-27 18:49:15
Documents
1
Period of Report
2022-07-25

Document Format Files

Seq Description Document Type Size
1 FORM 4 wf-form4_165896213456047.html 4  
1 FORM 4 wf-form4_165896213456047.xml 4 8250
  Complete submission text file 0001714899-22-000109.txt   9616
Mailing Address 1 DNA WAY SOUTH SAN FRANCISCO CA 94080
Business Address
Tessier-Lavigne Marc (Reporting) CIK: 0001437435 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38311 | Film No.: 221112282

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Issuer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)